BSE · 544529
Aptus Pharma Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹47 Cr with net profit ₹5 Cr — a 9.89% net margin, versus 12.58% the period before.
Shareholding
As of 2026-06-30
- Promoter72.89%
- Public27.11%
686 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 11.16× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — ESM · ESM 2. Trading may carry price bands, periodic call auction or higher margins.
- 52-week range spans 11.16× (₹32.32 to ₹360.6) — an unusually wide band.
Peer comparison
Trading · ranked #1 of 674 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Adani Enterprises Limited | ₹3,95,635 Cr | 153.69 | 4.18 | 3.93% | 6.78% |
| Avenue Supermarts Limited | ₹2,42,062 Cr | 79.15 | 9.9 | 12.14% | 4.29% |
| Trent Ltd. | ₹1,48,718 Cr | 81.34 | 21.35 | 24.62% | 8.64% |
| FSN E-Commerce Ventures Ltd. | ₹92,732 Cr | 348.12 | 64.46 | 13.87% | 2.41% |
| Aegis Logistics Limited | ₹47,518 Cr | 37.97 | 7.84 | 14.83% | 13.95% |
| Vishal Mega Mart Limited | ₹47,429 Cr | 53.28 | 6.38 | 11.32% | 6.61% |
| Aditya Infotech Limited | ₹39,967 Cr | 83.75 | 21.27 | 19.61% | 9.77% |
| Premier Energies Limited | ₹39,948 Cr | 23.99 | 9.3 | 35.05% | 19.67% |
| Redington Limited | ₹31,279 Cr | 17.39 | 3.08 | 14.67% | 1.33% |
| Honasa Consumer Limited | ₹15,000 Cr | 59.44 | 10.63 | 14.16% | 9.75% |
| Aptus Pharma Limited(this company) | — | — | — | — | — |
AI analysis
AI-generated · google/gemini-2.5-flashAptus Pharma Limited is listed on the Indian markets. The company reported annual revenue of Rs 24.64 Cr for the year ending March 2025. Promoter holding stood at 72.89% as of June 30, 2026. The company is currently under ESM surveillance.
Positives
- +Annual revenue has consistently increased, reaching Rs 24.64 Cr in March 2025.
- +Net profit has shown growth, rising to Rs 3.10 Cr in March 2025 from Rs 0.19 Cr in March 2023.
- +Promoter shareholding is at a high level of 72.89% as of June 30, 2026.
- +There are no shares pledged by the promoters.
Negatives
- −The debt-to-equity ratio is 1.79, indicating a reliance on debt financing.
- −The company has not disclosed any quarterly results since March 2025.
- −Institutional and FII holding was 0% as of June 30, 2026.
- −The company is under ESM surveillance.
- −The number of shareholders has increased from 213 in June 2025 to 686 in June 2026, which may indicate increased retail interest without corresponding institutional backing.
Financial Performance
Aptus Pharma Limited's annual revenue increased to Rs 24.64 Cr in March 2025 from Rs 17.88 Cr in March 2024. Net profit also rose to Rs 3.10 Cr in March 2025 from Rs 0.80 Cr in March 2024. Earnings per share (EPS) grew to Rs 6.37 in March 2025 from Rs 5.32 in March 2024.
Profitability & Returns
The company's EBITDA showed growth, increasing to Rs 4.66 Cr in March 2025 from Rs 1.36 Cr in March 2024. Net profit also improved significantly over this period, reaching Rs 3.10 Cr in March 2025 compared to Rs 0.80 Cr in March 2024.
Balance Sheet
As per the available data, the company has a debt-to-equity ratio of 1.79. No other balance sheet items were provided in the dataset, such as total assets, liabilities, or equity, making a comprehensive assessment of the company's financial structure limited.
Ownership & Pledges
Promoter holding in Aptus Pharma Limited was 72.89% as of June 30, 2026. Public shareholding was 27.11% in the same period. There were no shares pledged by the promoters. Institutional and FII holding was 0% as of June 30, 2026.
Regulatory & Surveillance
Aptus Pharma Limited is currently under ESM (Enhanced Surveillance Measure) Stage 1 surveillance, which indicates that the stock is subject to additional monitoring by regulatory authorities. This measure is implemented to enhance market integrity and protect investor interest.
Data as of — price: 2026-09-18 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.